Hydroxyurea Therapy for Children With Sickle Cell Anemia in Sub‐Saharan Africa: Rationale and Design of the REACH Trial
Pediatric Blood & Cancer2015Vol. 63(1), pp. 98–104
Citations Over TimeTop 10% of 2015 papers
Patrick T. McGann, Léon Tshilolo, Brígida Santos, George Tomlinson, Susan E. Stuber, Teresa Latham, Banu Aygün, Stephen Obaro, Peter Olupot‐Olupot, Thomas N. Williams, Isaac Odame, Russell E. Ware, for the REACH Investigators
Abstract
REACH will provide data that address critical gaps in knowledge for the treatment of SCA in sub-Saharan Africa. By developing local expertise with the use of hydroxyurea and helping to establish treatment guidelines, the REACH trial results will have the potential to transform care for children with SCA in Africa.
Related Papers
- → Moskowitz JT, Butensky E, Harmatz P, Vichinsky E, Heyman MB, Acree M, Wrubel J, Wilson L, Folkman S. Caregiving time in sickle cell disease: Psychological effects in maternal caregivers. Pediatr Blood Cancer 2007;48:64–71.(2008)9 cited
- → Children's Oncology Group's 2013 blueprint for research: Neuroblastoma. Pediatr Blood Cancer 2013;60:985–993(2014)1 cited
- → Nursing Facility (NF) Residents with Anemia Associated with Chronic Kidney Disease (CKD) Require Greater Assistance in Performing Activities of Daily Living (ADL) Compared to Residents with CKD without Anemia.(2006)
- → [Diagnosis and treatment status of perioperative anemia in patients with gastrointestinal neoplasms: a multi-center study in Hubei Province].(2022)
- → Anemia in patients admitted to a hospital in Teixeira Soares-PR(2023)